Sutro Biopharma (STRO) Return on Sales (2017 - 2025)
Historic Return on Sales for Sutro Biopharma (STRO) over the last 9 years, with Q3 2025 value amounting to 5.87%.
- Sutro Biopharma's Return on Sales fell 1400.0% to 5.87% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.19%, marking a year-over-year decrease of 13800.0%. This contributed to the annual value of 3.67% for FY2024, which is 29700.0% down from last year.
- Per Sutro Biopharma's latest filing, its Return on Sales stood at 5.87% for Q3 2025, which was down 1400.0% from 0.18% recorded in Q2 2025.
- Over the past 5 years, Sutro Biopharma's Return on Sales peaked at 0.27% during Q4 2023, and registered a low of 11.46% during Q1 2025.
- For the 5-year period, Sutro Biopharma's Return on Sales averaged around 3.51%, with its median value being 3.63% (2021).
- Its Return on Sales has fluctuated over the past 5 years, first skyrocketed by 42800bps in 2023, then tumbled by -69900bps in 2025.
- Quarter analysis of 5 years shows Sutro Biopharma's Return on Sales stood at 3.58% in 2021, then fell by -12bps to 4.01% in 2022, then surged by 107bps to 0.27% in 2023, then plummeted by -1892bps to 4.89% in 2024, then dropped by -20bps to 5.87% in 2025.
- Its Return on Sales stands at 5.87% for Q3 2025, versus 0.18% for Q2 2025 and 11.46% for Q1 2025.